>> pfizer c.e.o. dr. albert bourl this week on "firing line." with margaret hoov" is made possle in part by... corporate funding is provided by... >> welcome to "firing line," albert bourl >> thank you very much, margaret. >> dr. bourla, t question on everyone's mind is, when will average americans realistically be able to get the covid-19 >> i believe, sometime in the next year -- maybe the third or the second quarter. inand the reason why i'm s that -- we will be able to provide to the american people around 20 million doses or more this year. but this is 10 million people with two does, and i'm sure that the alth authorities would like to use them strategically. so, at the beginning, who will get the vaccine will be predetermined by them.as and likely, me, it will be people either with high risk or first-lineorkers. so i believe that we will reach a level around second quarter that maybe people can just go and get them in thr pharmacies or at the physician office at their will. >> do you think, by next

did pfizer elect biden? to go down to georgia and spend millions to make sure that the senate doesn't go republican. i think that's certainly could happen i am sure there are plenty of people in this country angry that pfizer withheld information. david, you know that has to be a theme. >> it's without a doubt. it's being discussed and questioned and i'm also looking at things here that indicate that was not the case. the ceo was asked about that didn't pfizer say the event rate in the trial was in the ballpark of 11.1% per month and protocol was the question and what happened why did they do away with the first interim look at 32 events meaning symptommatic and pfizer says in order to do so was accumulating samples but not analyzing them pfizer was very focused on so there won't be any accusation of they saw something and now they want to change the protocol. so, i don't think you're going to find much satisfaction going down that road if you are saying in some way that they withheld or could have told us s

>> pfizer c.e.o. dr. bert bourla, this week o "firing line." >> "firing line m withgaret hoover" is made possible in part by... corporate funding is provided by... >> welcome to "firing line," albert bourla. >> thank you very much, margar. >> d bourla, the question on everyone's mind is, when will average americans realistically be able to get the covid-19 vaccine? >> i believe, sometime in the next year -- maybe the third ord the seuarter. and the reason why i'm saying that -- we wl be able to provide to the american people around 20 million doses or more this year. but this is 10 million people the health authoriould sure that like to use them strategically. so, at the beginning, who will get the vaccine will be predetermined by them.d kely, i assume, it will be people either with high risk or first-line workers. so i believe that we will reach a level around second quarter that maybe people can just go or at the physician officemacies at their will. >> do you think, by next summer? >> i think so. >

pfizer and what it now says about its vaccine for coronavirus. the head of pfizer saying he learned just 24 hours ago of the results, that human trials show its vaccine candidate for coronavirus is 90% effective at fighting the virus. late today, dr. anthony fauci calling the test results extraordinary. the drugmaker did not take u.s. federal money to keep their vaccine from being politicized and will next turn to the fda for emergency use authorization. so, tonight, what does this mean for americans? how many million doses by the end of the year and for whom? and when will the rest of the country have access to a vaccine? and all of it tonight as this country sees several days in a row now of well more than 100,000 new cases a day. tonight, the virus on the rise in 49 states. and this evening, the newest covid outbreak inside the white house. secretary ben carson, who is a doctor, testing positive, he was at the white house on election night. after the president's chief of staff tests positive, too. and now the top outside adviser leading presid

was it the first time pfizer was trying it? how much is at stake for the medical community if this works in terms of the covid vaccine? >> yeah, that's a great question i think that the debate if you go back over the last year or two has been on the novel and innovative science that has been looked at here but has not been fully proven out like i think you sort of eluded to. pfizer i think put a stake in the ground as a huge sign of val days, which is part of why people are excited about this and proving out today with the data moderna did have partnerships with merck and with others and continues along that path. moderna didn't need capital. i think they will show that in the next few weeks when their data comes about so bottom line is i feel very excited about the platform and these technologies >> but if pfizer can use this approach successfully, perhaps other big biotech companies will do the same thing, why would you need moderna >> well, i think some of the things that meg said i think are absolutely true and i would echo

well, i'll let pfizer -- i'm on the board of pfizer one of the companies that has a vaccine i'm not prooifrom any ress from moderna i would expect to see continued data with the trials with the therapeutic antibodies the fda has been reviewing the data for a while now so i want kppd a regulatory decision probably emergency use authorization imminently on those. a lot of us expected that to happen based on the data that's available. those could be available in the near-term. enough supply to have some impact on the spread that's underway to target those drugs to high risk individuals >> dr. gottlieb, i want to clarify something you said earlier about this transition, you believe that the administration is going to be working with the biden administration or the president-elect biden's transition team irrespective of whether the president concedes >> well, the bottom line is that there's interactions going on. there's very formal process in place for transitions between administrations. some of this was put in place after 9/11, a recognition you needed a smooth handoff between administration

that is pfizer vaccine.s out saying they are going to have o potentially a vaccine in place by the end of november, if they can get the emergency use and wire wider usage 90%, effective the president made this a priority, asked pharmaceutical companies do this in warp speed, even if the pfizer wasn't part of that warp speed program, what is the president saying now about this effectiveness of this pfizer drug, now 90% effective causing a massive stock market rally this morning. >> maria, this is great news operation warp speedy president trump getting cure to this virus we are one step closer to having life back to normal a key difference. >> job talking about staying in basement he potentially needing to lock down economy in january you won't see stock market reacting this way if folks thought economy would get shut down in january we are going to defeat this virus great news as we talked about everything the president accomplished so far keeps on doing even after election still accomplishing great things m

beyond taken pfizer and now planning to apply later this month for emergency use approval in the u.s. even if it all goes well authorities have stressed it's unlikely any vaccine will arrive before the end of the year. now let's get more we are joined now by peter crams now director of the institute for tropical medicine at the university hospital in tubing and he's also leading the clinical trials of a covert $1000.00 vaccine which is developed by german biotech company sure vaca welcome to the program and thank you so much for joining us i want to talk about the vaccine that you're working to develop at 1st i'd like to get your reaction because we have biotech pfizer saying that they succeeded in reducing the risk of cova 1000 by 90 percent in an efficacy study what is your reaction to that going to do this. one of these news. and i don't know the press release. or any other company commission on this you see these 2 would use condensed in the 1st few nice that you know no serious of those grounds and that the issue is 90 percent to untouched talk with us about now your efforts beca

they are supposed to regulate pfizer. not be in bed with pfizer.hink a huge deal and i will add one more. eli lilly this week, you remember on monday you got announcement about an antiviral drug, another breakthrough medicine, it's huge. it's really important for people who get coronavirus to get treated. we found out about this -- that eli lilly emergency use operation sent to the fda a month ago. it took over a month for them to approve this and they did it one business day after the media declared joe biden to be the victor. >> tucker: a lot of federal dollars, a lot of tax dollars moving towards these pharma companies. vaccine are good business, so it's not a bad thing to make a big time vaccine. i think we have a right to know more about this i hope you will stay on it. vince, thank you for your reporting. >> thanks so much, tucker. >> tucker: so much more ahead tonight, but first the latest print advertisement just out from the joe biden team, you'll want to see this. ♪ >> tucker: it's veterans day. we want to close tonight by honoring a vete

the pfizer vaccine just about here. not a moment too soon. i want to bring in dr. ashish jha, dean of brown university school of public health. and dr. jha, last week, you said the evefficacy was just outstanding, and that's before we learned it's now even better. 95% and close to that for our seniors. >> yeah, this is terrific news, david. so, i'm pleased to be back on and to be able to say between this and the moderna vaccine, it looks like we have two vaccines that are going to end up being very effective. once they are widely deployed, it's going to make a huge difference in bringing the pandemic under control. >> and dr. jha, you heard pfizer say as soon as they get fda approval, they're going to start shipping within hours. we know it has to be kept at temperatures 94 degrees below zero. we saw the freezer-like boxes in tom's report. you're convinced they'll be able to pull this off? and when will most americans potentially get access? >> reporter: so, i am convinced that we're going to be able to pull this off. i mean, there's a lot of logistical challenges

congratulations to pfizer. congratulations to pfizer. >> yeah. >> i can't wait to get rid this thing. >> congratulations to pfizer and all of that. >> that's right. >> not yet don't get rid of the mask just yet, nelson. >> no, i'm not >> how are you thinking about what this is going the mean to the markets? >> look, we have already seen it we are having a great year today. i mean it was a hell of a year so far for those of us who like stable staples and were long today was sort of a new beginning for all of us. so we're thrilled with what happened today mu mo but more importantly, sara, i'm thrilled for american. and i'm thrilled for the rest of the world. this is the way out. i have got give kudos to the administration for speeding this research up, for making this happen in record-breaking time we've never seen a drug come to market so quickly and obviously so effectively so i'm thrilled. i'm thrilled for everybody i think it is going to be great for the economy. >> does it make you want to put more money int

tom: what is the next step for pfizer? what is phase fazeli right now for pfizer? sam: they have a pretty decent number to go to the regulators and ask for emergency use authorization. unfortunately we have to check our enthusiasm a bit, continue to wear our masks and keep our distance, because we've only got 50 million doses by the end of the year. next year is a different story. but don't forget, the next one we will hear from will be but debts will be moderna -- will be moderna. it may not be as effective, but will still be a useful weapon in trying to get as many people vaccinated as possible. lisa: that's exec he where i wanted to go, the rollout of these vaccines, how quickly we could try to stop the covid surge we are seeing now. how likely is it that the safety data we are looking for is going to be sufficient to give people confidence to start unrolling this in billions of doses? sam: you are going to have to accept some risk. orn we get to next week thereabouts, pfizer should have about two months of data on about 20,000 people, did thousand of whom would

the pfizer vaccine just about here. i want to bring in dr. ashish hh j jha. you said last year the every fa si was just outstanding last weeking and that's before we learned this week it's even better. 95% and close to that for our seniors. >> yeah, this is terrific news, david. so, i'm pleased to be back on and to be able to say between this and the moderna vaccine, it looks like we have two vaek seens that are going to be very effective. once they are widely deployed, it's going to make a huge difference in bringing the pandemic under control. >> and you heard pfizer say they're going to start shipping within hours. we know it has to be kept at temperatures, 9d 4 degrees below see roer. we saw the freezer-like boxes in tom's report. when will most americans potentially get access? >> reporter: so, i am convinced that we're going to be able to pull this off. there's a lot of challenges here, but states are starting to work hard on getting ready to receive these things. about 10 million americans in december, 10 million in january, those are going to be the h

pfizer and its partner biontech, look at this, 52-week highs. stocks overall did hit record highs but closed, well, well off of them. the dow, s&p 500, certainly higher but no closing high there. the nasdaq it turns negative in the end as the big momentum players stalled out. so in the mind of investors this is what is going on. first, no blue wave, a promise for vaccine allowed to return to normal. that is why you see the cheap beaten down travel retail entertainment names soaring today hope is sometime in the near future when a vaccine is widely available, that is the key word, widely, these parts of the economy will be held back. look at that amc up 451%. on the flipside, this was part of the weakness in the nasdaq, those big momentum stocks that surged since the lockdown they struggled today on the idea of us getting off of our couches and the world opening back up. so there is a word of caution. also the fda would still need to green light pfizer's vaccine even if that happens next month and then distribution can start it will be limited in

jumped over 7%, and surprise that shares of pfizer jumped over7%, and it surprise that shares of pfizering the vaccine used as fantastic, especially in europe and the us, developing this vaccine alongside biontech, and some of the countries that have been seeking the access to these technology companies, zoom, amazon, netflix, they have fallen back so we are watching the markets. let's get some of the day's other news. at least 50 people have died in honduras since storm eta hit central america last week. a relief operation is underway in the country's economic heartland in the sula valey. the storm left a trail of destruction through central america after it made landfall in nicaragua on tuesday. in guatemala, around 150 people died or are missing in landslides. myanmar‘s ruling party is claiming a resounding victory in the country's second parliamentary election since the end of its military rule. sunday's election was viewed as a referendum on its leader aung san suu kyi and her national league for democracy party. it remains popular at home, but has been highly critized overseas ove

so let me ask you about this pfizer news then. pfizer and biotech -- >> i lost all contact here. can you hear me now? are you with me? dr. olsterhom. we will get the communication back in a moment, but i guess, what you just heard there, dagen, in terms of the severity that he's expecting in the coming weeks and months tells you that we may very well be in for some -- more aggressive moves to counter and to control this virus. dagen: i just want to point out one thing because i watched this every single day,fully the case fatality rate. the case fatality ratio on the johnson hopkins university website and in terms of the case fatality rate, i think that this is deaths per 100,000 people in the population, the united states is still at 2.4%, that is below mÉxico, iran, italy, united kingdom, indonesia, spain, colombia, argentina, excuse me, belgium, romania and that puts us -- maria: the u.s. is doing better in those countries is what you're saying? dagen: it's holding steady as the potentially spreads in the united states, nevertheless it's been holding steady at 2.4%. maria: wha

these are very complicated vaccines, especially pfizer and modernity. they are based on a new technology called messenger rna. there is a requirement to make the vaccine that is not typical. you need to get the , these fatty containers that you can carry the -- it is complex stuff and it requires hunting the globe to find these things in many different developers are making them. it will be interesting to see. if one appears to be highly effective as we get more data, what another pharmaceutical company volunteer its own manufacturing power, or would a government step in and say we are going to try to impel you to do this? that is something i'm watching very closely. we haven't seen that yet. i think it is due to the complex city of the biology. these are not pills coming off the supply chain line, these are really complex, intricate medicines to develop. host: craig and washington, d.c., line for democrats. caller: good morning. i wanted to -- i see a lot of people you're dying a lot and going to the hospital. i would like to know is it possible that p

rate is what we saw, i higher efficacy rate then pfizer. last week, people were talking about pfizer and how it had to be kept at ultracold to birchers until a couple of days before it was distributed -- ultracold temperatures until a couple of days before it was distributed. this one has a 30 day shelf life at standard refrigeration. this is very promising, and we are seeing a reaction in markets. jonathan: they are the headlines. let's plug them into the financial markets. there is the pop on what irna. equity futures in the united states, on the s&p 500 come on the nasdaq, and on the russell as well. futures, up russell by a little more than 2%. a record high at the close on friday in the russell, and we advance once again. i want to check in on the bond market. yields higher, curve steeper. switch of the board. bonds lower, yields higher, up three basis points on tens. on 30's, we advance three basis points. in the space of one week, improving news on the vaccine front from pfizer, and now moderna, at a time when infections in the unite

this pfizer vaccine was. —— optimism ladder.be optimistic? because vaccine development is hard. vaccine development is slow. but vaccine development is beset by many, many hurdles. and what we have today is interim early results from a vaccine modality that has never, ever been licensed before. so i think "cautious optimism" is a really good phrase that we use for where we are today. it's great to see the world's vaccine community come together and develop these creative, novel ways to deal with what is the scourge of humanity at the moment, covid—19. president—elect biden has made the fight against climate change one of his top four priorities calling for net zero carbon emissions by 2050. 0ur science editor david shukman looks at the possible impact that a biden presidency could have on global efforts to tackle climate change. the battle to save our planet by getting climate under control. joe biden believes the changing climate is an urgent threat, unlike donald trump, who withdrew from the only international agreement to tac

if you can first respond to the pfizer announcement yesterday.ront and come after say it is great ne. it is always encouraging to see positive results in vaccine trial, especially at this stage in an epidemic. very quickly. you know, it is hopeful. but it is only a press release. there has been no scientific release. there is no published dat we don't have anything to go with except with the lawyers at pfizer massaged carefully into a single page press release. so we have to take that with a big caviar. the other thing that has to be considered careful is that this precedent is in the process of carrying out retribution's commitment did for firings all across his government, getting rid of people who have stood up i him in various agencies -- mean, the most astounding yesterday, firing the secretary of defense. in stephen hahn, the head of fda, has been consistently on trump's hit list. he stood up to the president regarding hydroxychloroquine, regarding plasma therapy, and other things that the president claims would treat work here or eliminate

pfizer comes at a minimum package of 975 doses per tray. and moderna comes in at 100 doses per tray. with that said, though that only a constrain because of what we have to do to maintain it at the right temperature for stability. so, you can break down both vaccines, all right. you can pull out quantities of what you want to execute and put them -- reduce them and put them into a normal refrigeration and execute them within five days. that's the key. so, it's the planning, the specified execution that we're counting on. and the states have been working this. one of the reasons that we asked and we brought walgreens and cvs special as the secretary mentioned is because they know how to break this down and do small quantities for important groups. and so, we've worked very detailed plans with them. and we're collaborating that with the jurisdictions to make sure that no vaccine is wasted and that when they go to immunize at specified places, they have the right techniques and procedures to make sure that only the required doses are reduced t

at pfizer headquarters in new york city. it's 11:00 a.m. on wall street and "squawk alley" is live ♪ >>> good monday morning. i'm carl quintanilla with jon fortt. the dow puts together the first intraday high in nine months, processing the election, putting closure, perhaps, to that but obviously the big news of the day is out of pfizer and this potential covid-19 vaccine once again, we'll start the hour with meg >> hey, carl this news that pfizer and german partner biontech provided 90% efficacy in the phase three trial providing hope this is the first vaccine we have seen results from the results are limited. they just -- the independent committee took a look at the trial. they found 94 confirmed cases of the covid-19 in the trial and they found a difference in the placebo group and the vaccine group. they also said they saw no serious safety concerns in the trial. they're going to he mass two months of safety followup which for half the people in the trial getting their second shot which will take them into the third week of november tha

pfizer stock. so for 27 years, i accumulated the stock. ofet this up in february i said i wanted for the first time in my life to sell shares. and i renewed the plan with the exact same conditions and i did it for one year. in fact on monday, i didn't know that i sold the stocks. i didn't sell as an administrator. i never saw the stock price when askingor the price i was . me, it's because for i became some that famous, and from a hero to what you saw in one day. i was very happy, then i was devastated and i saw what was written. i wish i didn't have to deal with that, but as i said, it's coming. it comes with the territory. you change the program going forward? meaning are you going to end the program? albert: i don't have any other program right now. that was the first i ever did in my life. that's a first time that i ever .old any shares thene final question, pharma industry has long been considered a villain oftentimes in washington and in the public sphere. changethink that will with the vacci

sold any pfizer stocks for 27 years i accumulate only. and i have said this plan in february and of 2020 and i set the price and i set the volume that i wanted to first time in my life-- sell shares and i had the exact same conditions price and volumes when the plan was close to expiration for one year. in fact on monday, i didn't know i sell, as an administrator, and never sold the stock price going bold when i monitor the price asking apparently went and i couldn't see it in the diagram and that was sold. i regret because for me, now, i'm-- it's the first time that i become so famous and from a hero to a why you sold in one day and you know, it was, you know, i was very happy then i was devastated when i saw what was written. yeah, i wish i didn't have to deal with that. but as i said, it's-- it's coming, it comes with the territory. >> two quick follow-ups, will you change the program going forward? >> change what? >> will you change the forward going forward? are you going to end the program? >> i don't have any other program right no

the drug company pfizer says it's a great day for science, but others urge caution. prime minister says the nhs will be ready for its roll—out. we have cleared one significant hurdle but there are several more to go before we know the vaccine can be used. hundreds of thousands of tests are being dispatched by the government to local authorities in a further move towards government targets. the us president electjoe biden says tackling the pandemic is his first priority as the country's number of cases hit 10 million. we have to come together to heal the soul of this country, so that we can effectively address this crisis as one country. and 25 years after the disability discrimination act, why many disabled people still can't access what they need. good evening, and welcome to the bbc news. could this be the news we've all been waiting for? preliminary results suggest a new vaccine has been developed that can prevent more than 90% of people getting coronavirus. the pharmaceutical giant pfizer and its partner biontech have tested their vaccine on 43,500 people in six

for pfizer and biontech?ible. i think that the fact that we have more than one to choose from because there's going to be such a demand, this is the actual -- the entire world needs to be vaccinated. so the more companies that are out there the better it is. i don't think we can think of trading one off for the other. i think we're going to have a menu. i think that's the best situation to be able to choose from. the more capacity we have, the more vaccines, the better. maria: dagen mcdowell, jump in. dagen: i would point out and dr. adalja touched on this that the pfizer vaccine requires ultra cold storage of -- it's like more than negligence difficult -- it's about negative 94 degrees paren fahrenheit so s moderna vaccine can be stored in a refrigerator and kept stable for 30 of days that, would give the moderna vaccine potentially a leg up. ups is working on a freezer farm in kentucky, just to deliver the pfizer vaccine. but dr. adalja, a quick question. how many vaccines do you think in the united states

this is how pfizer and moderna have developed their potent vaccines.t, we need all of these techniques at the moment because we still do not know which will prove to be best. that's a very clear explanation of all the different vaccines. let's speak to paul duprex, a virologist and the director of the centre for vaccine research at the university of pittsburgh in the us. thanks forjoining us. we saw there a quite clear explanation of all the different vaccines. let's talk about the pfizer vaccine primarily because it is it the news today. what makes the pfizer vaccine different to the other ones and so new? that was a beautiful expiration of the four big buckets of vaccines. let's just focus on that pfizer one, the one that we covered last, and what you're doing in that developmental approach to vaccines is you are not using the lab to make proteins, you're using the person to make the proteins, and that despite protein is the key protein which, again, the report discussed, these antibodies that protect us from the disease are developed against. so the

pfizer was to be expected.f talk about that today but they thought it would be mid to late november. they're out a week or two early. you will see more good news out of regeneron. the cancer pipeline is more robust than covid vaccines. the other name worth looking at a layup for coronavirus theme trades in my opinion is abbott laboratories. they dot rapid testing. i don't think you can go forward while this is part of our country and part of our economy without the rapid testing. both names were down today. what you should be looking at a name like today with a huge rally is find some of the losers and this is where you can get involved. charles: all right. cheryl mentioned building materials, warehouse gigs. we know that is reflective of home depot, walmart, amazon, are you buying any of those names? >> i love all those names right now. what we saw in the last quarter of earnings, what we're seeing now, people are not really going on vacations. so a lot of that wallet share is going towards improving our homes

first, pfizer announced very promising data on its vaccine candidate.econd, eli second, the fda authorized and we have begun to distribute and administer eli lilly's monoclonal antibody to help americans at risk for serious disease stay out of the hospital. third, another vaccine company, moderna, announced that it's reached a critical clinical trial milestone, meaning we may see data from them within days. back in the spring, we were told by all of the experts that a vaccine was a year or a year and a half away, and the announcements i just highlighted would have been unthinkable. the president said, that's not acceptable. and thanks to the support he's provided, we're now on track to deliver a safe and effective vaccine to our most vulnerable this year. as i worked with the president to assemble this team and organize this effort, his support was indispensable at each step of the way. we went out and found the very best people on the planet to do the job, who you just talked with. dr. slaoui, the world's most successful vaccine developer. general pern

pfizer is in the lead right now. you've got madonna coming up close behind that you've also got astra, zeneca and johnson. and johnson close behind. so there's a few differences between some of these vaccines, but hopefully the public at large will also be able to take advantage of these millions of doses that are on standby once the f.d.a. approves them. well, with the upcoming holidays is going to slow the process. how long will it be before the f.d.a. actually review the documents? approve them and then the steps going forward from there. right. i know,, and it seems like it's so subjective sometimes with the f.d.a., but, you know, we have the cases that are getting worse than ever. the numbers are climbing continually. you have new york which shut down public schools. and of course, we're seeing increased hospitalizations around the country, so the f.d.a. knows that this needs to happen, that finding an effective vaccine that the public is actually willing to use is an important part of controlling the coronaviru

as a result, pfizer says the vaccine is more than 90% effective.at day for science and humanity. you know, i've never felt, professionally, such a moment ofjoy. and we werejust jumping up and down with joy for humanity, joy for medical advances, to put an end to this dreadful pandemic. the vaccine uses a tiny amount of the genetic sequence of the spike protein which sits on the surface of coronavirus. synthetic material, known as rna, is injected into muscle cells in the arm. this stimulates the creation of antibodies — y—shaped proteins, which should bind onto coronavirus, preventing future infections. killer t cells are also produced. these should identify and destroy cells which have become infected. scientists around the world have moved at an extraordinary pace to develop coronavirus vaccines. there are 47 in human trials. the uk government has advance orders for six of them, including 40 million doses of the pfizer—biontech vaccine. that's enough to immunise 20 million people, as you need two doses. pfizer says by the end of the year, 50 mill

the pfizer achievement is significant. their challenge, freezer farmers in kentucky, transportation hubs that is already in place. they will not need -- i actually think that there is a very big difference between president trump's policy for the pandemic planning at this stage compared to what joe biden is suggesting. joe biden wants to accelerate funding for escalating rapid testing across the country. thinking about mask mandates. those have their uses, but we are now in the absolute sick of the pandemic, and we need to be planning a mass vaccination program in the united states. that is where all of the main focus should go. we are going to have half of a dozen vaccine candidates very soon. it is a technology which has never been successful before. modernity, johnson & johnson will be on the heels with one injection only. the others need to injections, so we need massive mobilization of the logistics of vaccinating americans. i think that is probably even a greater prayer widespread rapid testing, which we already have

and washington coming out as promised, pfizer. haas emitted its emergency use application for the cove in 1000 vaccine to the food and drug administration. a process that could start in limited 1st shot as early as next. month and u.s. treasury secretary steven, announced cut off for the federal reserve's lending program and hopes to restart stimulus talks, and hopefully will resume negotiations. to see i standing by have a lot to get through. so i get started. pharmaceutical giant pfizer is filing for emergency authorization of its crown of arsenic seen in the united states. the company is one of many working to fight the spread of cove 19. and as alex mohill of its reports, it is one of a few front runners that may help on the pandemic. the bottles are full and ready to go. once given the green light, pfizer says that it could start shipping out its coronavirus vaccine within a couple of hours. if the value i, we have already produced more than 20000000 doses in our warehouses and to continue as a state producing more and more t

we are cooperating with pfizer and it's one of the most experienced vaccines developers. pfizer has been through logistics. maria: it'll be distributed in the united states first? i know that you have commitments to developed countries x china and the china talks are ongoing but the united states will be first? >> the supply of the vaccine depends on a potential -- we are in communication with the fda in the united states and an organization that is, in japan and if we get an emergency use auto musician from the fda we will be able to supply to europe and a requirement for supply. maria: my thanks to ugur sahin, up next socia are you frustrated with your weight and health? it's time for aerotrainer, a more effective total body fitness solution. (announcer) aerotrainer's ergodynamic design and four patented air chambers create maximum muscle activation for better results in less time, all while maintaining safe, correct form. aerotrainer's unique design allows for over 20 exercises for a total body workout. plus, you can easily transition from one exercise to the next. wan

shesh outnd obout ahehe pfizer l tr weroing doingoin bon.bon.dndot ihehe ey told semysesendseeee c oe.ll oe. we wwe we accteccd.tepantticipat oirsfirs testou f cov t t make see y w't wovid sitive bo y wifee aro aroro i i wer wer tive theythdministhtethd are v vne.ci iv actualualne.ive receia ralace y't kw.w. it iit i i stili stl canlanl say s d seli t real r. h h thehe fir vacne, as ias aug i hadad aitf aa a not nike what happens with a flu shot. i had some slight chills. it resolved the next day. i had a booster shot a month later. i similarly had a sore arm, nothing serious. i had slight chills. it went away after a day. i went to have a antibody test in october. the antibody test received i had very strong antibodies there are two kinds of antibodies, a the best kind and better kind. i had the best kind of antibodies. i can't say i got the actual vaccine but there is a hint i probably did. the reason my wife and i did this we wanted to make sure we help science to get a vaccine out as quickly as safely as possible. we'll not end this pandemic

robert has a question about this pfizer vaccine.hether it had anything to do with the white house. do you know if this was privately funded or did it result from some sort of trump administration partnership with pfizer? >> i thought it was really interesting strategy not to affiliate with any politics. so pfizer is probably the only company i know in the running that did all of their development by themselves and didn't -- wasn't actually part of operation warp speed and so quote the pfizer ceo when he made the statement, he found it very important to distance himself from politics so that there will be no strings attached. >> all right. sasha says this vaccine is free for everyone. president-elect biden said the vaccine would be free to everyone. so we know, what is the true cost, if you can put a price on it, of a vaccine such as this? >> the costs to produce it will probably be in the billions of -- billion range and if you had to pay for it, you'd talking about a cost of one to $200 per course per person. >> wow. all right. so

pfizer upping the effectiveness of its vaccine overnight. that's updated straight ahead. >>> and let it rain, let it rain. it's wet out there this morning for you. but how long will that rain stick around? we are tracking it all for you as the third hour of "today in the bay" continues right now. and a good wednesday morning. i'm marcus washington. >> and i'm laura garcia. a rainy day yesterday. how long will it continue today, kari? >>> mostly for the morning we'll see the rain tapering off. it's adding up and we're tracking it on storm ranger. the peninsula and so we're seeing some of the wettest roads right now in the south bay. we are watching this closely as it continues to move through. it's good to see the rain returning. we'll track what's ahead as we go into the rest of the afternoon. the chilly air settles in. more on that coming up in a few minutes. mike, this is having a big impact on the morning commute. >> it is, kari. a word of caution, leave with plenty of time and the rain and kari's green will show up as green on ours a few

it's obviously not just pfizer. they're going to need a lot of government coordination to roll this thing out. >> right. well, they said shortly they'll have something like 50,000 doses. that's not much when you consider the 330,000 americans. they are projecting that some time during the summer of 2021 they will have enough vaccines to protect a large segment of the population. but again, i think people ought to put this in perspective. what we're likely to get is something like the flu vaccine. it's not necessarily going to protect you from infection, and it may not work for everyone, but it should be useful for many people. and it should moderate the severity of disease that most people who receive the vaccine get. that's what we're likely to get. but it is good news. now some -- i think that's what we should be expecting at this point. >> doctor, i don't know who was calling you moments ago, but you might want to let them know at 9:00 every morning they could watch a really good show on msnbc and know that you'r

beyond taken pfizer and now planning to apply later this month for emergency use approval in the u.s. even if it all goes well authorities have stressed it's unlikely any vaccine will arrive before the end of the year. and germany's health minister has called the news very encouraging but he also warned against false expectations saying that the vaccine won't be available over night he urged people to remain cautious and keep socially distanced until they finally get vaccinated. knowing that there is a good chance that the next autumn and winter might be considerably better than this year that gives me and i hope gives other germans and europeans optimism confirms us in our approach we must look after one another particularly well this november of this winter in general stick to the rules of and on the of to personal and the lake and so out into space is a once in a century kind of situation it's exhausting it's the boreas and it's sometimes hard but knowing that it won't be forever can give us extra strength and support for the current situation. some for you that psyche and let's ge

the pfizer in the mid one off will pop it back? seems the oxford astra zeneca vaccine is going to be for your dose. so that means you can immunize someone. and as long as this vaccine turns out to be education say, which is looking good so far for about 8 euros per person, that's going to be the real game changer for the world. great insight bad john campbell, health analyst and collin, the u.k. . thank you. thank you, don. let's now continue in that regard. looking at some other developments in the coronavirus pandemic. donald trump jr. the eldest son of the u.s. president has tested positive for corona virus. he is the latest from family member to contract, covert 19, the president and the 1st lady recovered from their infections. in october, a large scale study at the oxford university shows that people infected with the virus are unlikely to catch it again for at least 6 months. the study involved more than $12000.00 health workers in the u.k. . officials in china say they are carrying out mass testing on 3000000 people in the